The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells
Open accessAbstract
We investigated the mechanism of action of LBH589, a novel broad-spectrum HDAC inhibitor belonging to the hydroxamate class, in Philadelphia chromosome-negative (Ph(-)) acute lymphoblastic leukemia (ALL). Two model human Ph(-) ALL cell lines (T-cell MOLT-4 and pre-B-cell Reh) were treated with LBH589 and evaluated for biologic and gene expression responses. Low nanomolar concentrations (IC(50): 5-20 nM) of LBH589 induced cell-cycle arrest, apoptosis, and histone (H3K9 and H4K8) hyperacetylation. LBH589 treatment increased mRNA levels of proapoptosis, growth arrest, and DNA damage repair genes including FANCG, FOXO3A, GADD45A, GADD45B, and GADD45G. The most dramatically expressed gene (up to 45-fold induction) observed after treatment with LBH589 is GADD45G. LBH589 treatment was associated with increased histone acetylation at the GADD45G promoter and phosphorylation of histone H2A.X. Furthermore, treatment with LBH589 was active against cultured primary Ph(-) ALL cells, including those from a relapsed patient, inducing loss of cell viability (up to 70%) and induction of GADD45G mRNA expression (up to 35-fold). Thus, LBH589 possesses potent growth inhibitory activity against including Ph(-) ALL cells associated with up-regulation of genes critical for DNA damage response and growth arrest. These findings provide a rationale for exploring the clinical activity of LBH589 in the treatment of patients with Ph(-) ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies showed that enhanced histone acetylation induced by HDACi allowed the overexpression of genes involved in cell cycle arrest such as cyclin-dependent kinase inhibitors or the growth arrest and DNA damage-inducible protein GADD45 gene family (11, 28, 40, 45-49).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,233
Pui, C., & Evans, W. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390907 · Cited by 841
Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G. A. N., Durrant, I. J., Luger, S. M., Marks, D. I., FRANKLIN, I. M., et al. (2006) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841
Gene expression changes associated with progression and response in chronic myeloid leukemia
Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510423103 · Cited by 583
Mitsiades, C. S., Mitsiades, N., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N. C., Gu, X., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 537
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
Prospects: Histone deacetylase inhibitors
Dokmanovic, M., & Marks, P. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20532 · Cited by 487
Histone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 448
Regulation of histone deacetylase activities
Sengupta, N., & Seto, E. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20179 · Cited by 357
Vairapandi, M., Balliet, A. G., Hoffman‐Liebermann, B., & Liebermann, D. A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10140 · Cited by 343
Research works printed but not linked: 1
- Scuto, 2004, Synergistic cytotoxic effects of a combination of a novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells [abstract]., Blood (ASH Annual Meeting Abstracts), 104, 546a
Cited by
Sorted by citations
Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
Berdasco, M., & Esteller, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.005 · Cited by 651
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 431
Trials with ‘epigenetic’ drugs: An update
Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 242
Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells
Rajendran, P., Ho, E., Williams, D. E., & Dashwood, R. H. (2011) · Clinical Epigenetics · doi:10.1186/1868-7083-3-4 · Cited by 220
Metadata
- Authors
- Scuto, A., Kirschbaum, M., Kowolik, C., Kretzner, L., Juhasz, A., Atadja, P., Pullarkat, V., Bhatia, R., Forman, S., Yen, Y., & Jove, R.
- Affiliations
- City Of Hope National Medical Center (US)
- Novartis Pharmaceuticals, Cambridge, MA
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-05-15
- Volume
- 111
- Issue
- 10
- Pages
- 5093-5100
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC2384136
- OpenAlex
- W2086799752
- Cited by
- 141
- References
- 53
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 13 · 2019: 9 · 2018: 5 · 2017: 4 · 2016: 7 · 2015: 6 · 2014: 8 · 2013: 8 · 2012: 15
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- W. M. Keck Foundation
- National Institutes of Health
- National Cancer Institute (R01CA055652)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- panobinostat, histone deacetylase inhibitors, Philadelphia chromosome-negative acute lymphoblastic leukemia, DNA damage response, apoptosis, GADD45G, histone acetylation, H2AX phosphorylation, FOXO3, cell cycle arrest, MOLT-4 cells, REH cells, relapsed leukemia
- MeSH terms
- Panobinostat, GADD45 Proteins, Acetylation, DNA Damage, Gene Expression Regulation, Histones, Humans, Hydroxamic Acids, Indoles, Tumor Cells, Cultured, Apoptosis, Intracellular Signaling Peptides and Proteins, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
